AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

[124] Although good epidemiologic data exist on the entire spectrum of drug-induced liver injury (DILI), [125,126] data on the incidence of cholestatic forms of DILI are scarce. Cholestatic liver ...

The Genomic and Exposomic Hepatobiology Lab at Mayo Clinic is applying genomic and exposomic approaches to better understand the pathogenesis to chronic cholestatic liver diseases. This step is ...

Peking University-led researchers have modified an existing treatment for liver disease that does not cause itchiness, a ...

Liver involvement in systemic amyloidosis is frequent but is rarely of clinical importance. Five patients with severe cholestatic jaundice are described and an additional 20 from published reports are ...

Addressing the challenge of cholestatic itch, the scientific community has been pursuing innovative solutions. Recently, researchers from Peking University, led by Professor Lei Xiaoguang, in ...

Keay Nakae, an analyst from Chardan Capital, maintained the Buy rating on ProQR (PRQR – Research Report). The associated price target is ...

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille ...

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting ...